The lowering of the price target from $25 to $20 by UBS suggests a less optimistic view on the stock's potential, which could lead to a negative short-term impact on the stock price. The Neutral rating indicates no strong buy or sell recommendation, but the reduced price target may influence investor sentiment negatively.